Famotidine clinical trials
Famotidine is named as an intervention in 6 current clinical trials in our USA, UK, France, Italy, Canada, Australia, South Korea, Taiwan and Egypt registers. 5 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Bristol-Myers Squibb (2). The most-studied condition is Healthy Volunteers.
Where Famotidine is approved
All regulators →Of the three regulators tracked here, the first to approve Famotidine was the US, on 15 Oct 1986. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Famotidine
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Famotidine works
All drug targets →- Histamine H2 receptor antagonist AntagonistTarget: HRH2 histamine receptor H2✓ In ChEMBL and the Guide to Pharmacology
- COVID-19Phase 3
- DysmenorrheaPhase 3
- FatiguePhase 3
- HeadachePhase 3
- PainPhase 3
- Sleep disturbancePhase 3
- Diffuse large B-cell lymphomaPhase 3
- DysautonomiaPhase 3
- GastritisPhase 3
- Peptic esophagitisPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL902, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7074, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Famotidine
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 7 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Famotidine
- ATC code
- A02BA03
- ChEMBL
- CHEMBL902
- DrugBank
- DB00927
- PubChem CID
- 5353622
- CAS number
- 76824-35-6
- FDA UNII
- 5QZO15J2Z8
- Wikidata
- Q411159
- Wikipedia
- Famotidine
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Famotidine
6 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Famotidine across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
7 single-substance products containing Famotidine on the HPRA medicines list.
- Famotidine Clonmel 20 mg film-coated tabletsClonmel Healthcare Ltd · PA0126/344/001 · Marketed
- Famotidine Clonmel 40 mg film-coated tabletsClonmel Healthcare Ltd · PA0126/344/002 · Marketed
- Pepcid AC 10 mg Film-coated TabletsJNTL Consumer Health I (Ireland) Limited · PA23490/032/001 · Marketed
- Famotidine 20 mg film-coated tabletsAmdipharm Limited · PA1142/043/001
- Famotidine 40 mg film-coated tabletsAmdipharm Limited · PA1142/043/002
Supply shortages
No entry for Famotidine in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Famotidine
9 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Bristol-Myers Squibb | 2 |
| Epkin | 1 |
| Seok Kyeong Oh | 1 |
| Buddhist Tzu Chi General Hospital | 1 |
| Sherief Abd-Elsalam | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Famotidine trials
How many clinical trials are testing Famotidine?
6 current trials in our USA, UK, France, Italy, Canada, Australia, South Korea, Taiwan and Egypt registers name Famotidine as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Famotidine trials recruiting patients?
Yes. 5 of the 6 trials are recruiting: 3 with sites in USA, 2 with sites in UK, 1 with sites in France, 1 with sites in Italy, 1 with sites in Canada, 1 with sites in Australia, 1 with sites in Taiwan and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Famotidine clinical trials?
Bristol-Myers Squibb (2), Epkin (1), Seok Kyeong Oh (1) and Buddhist Tzu Chi General Hospital (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Famotidine licensed in Ireland?
Yes. The HPRA medicines list includes 7 single-substance products containing Famotidine, for example Famotidine Clonmel 20 mg film-coated tablets (Clonmel Healthcare Ltd). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Famotidine shortage?
Not in the lists we track: Famotidine has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Famotidine works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Famotidine works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Famotidine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.